Two noteworthy developments in the study of diabetes came to light today. The first is the progress that has been achieved in the use of stem cells to "re-educate" the T cells in Type 1 diabetes (Univ. of Illinois). While reports on this research allude to "reversing" Type 1 diabetes, the actual research is better described (and more importantly) for illustrating that patients' pancreatic islet beta cells can have their insulin-producing function restored via immunomodulatory steps. Thus, Type 1 diabetics may potentially regain normal glucose regulation by repair — rather than by the more complex process of cell transplant.
The second development is that researchers at the La Jolla Institute for Allergy & Immunology have proven which T cells are responsible for destroying the pancreatic cells in Type 1 diabetes.
Both of these developments are important for the fact that they center on the actual mechanisms involved in the development of Type 1 diabetes and thereby accelerate the progress toward therapeutically intervening in order to restore normal insulin production.
The global market for products in the management of diabetes (for Types 1 and 2) is illustrated below.
Source: MedMarket Diligence, LLC; Report #D510, "Diabetes Management: Products, Technologies, Markets and Opportunities Worldwide 2009-2018."